Viatris completes Pacira deal and expands non-opioid pain portfolio

Viatris has completed its US$1.69 billion cash acquisition of Pacira BioSciences, taking full ownership of the non-opioid pain management company. Pacira is expected to contribute US$90 million to US$100 million in revenue over the remainder of 2026.

  • US$1.69 billion acquisition completed with cash and short-term borrowings
  • 66.46% of Pacira shares were validly tendered
  • Pacira becomes a wholly owned Viatris subsidiary
  • US$90 million to US$100 million expected 2026 revenue contribution
  • Pacira shares to be delisted from Nasdaq
An image related to Viatris Inc. A photo of the logo for Viatris Add us as a preferred source on Google
Image © middle. Logo © respective owner.

Viatris takes full ownership of Pacira

Viatris Inc. (NASDAQ:VTRS) has completed its acquisition of Pacira BioSciences, closing a US$1.69 billion transaction that expands the healthcare group’s position in non-opioid pain management. The purchase will be funded through a combination of cash on hand and short-term borrowings, excluding related fees and expenses.

The deal cleared its key ownership threshold after 32,929,780 Pacira shares were validly tendered and not withdrawn, representing approximately 66.46% of shares outstanding at the offer’s expiry. That was enough to satisfy the minimum condition, allowing the transaction to proceed without a vote of Pacira shareholders.

Pacira deal moves from offer to operating business

Pacira is now a wholly owned subsidiary of Viatris, following the merger of Viatris’ acquisition vehicle into Pacira. Shares not tendered were converted into the right to receive US$36.50 in cash, subject to the transaction’s terms, while Pacira’s shares are set to be delisted from the Nasdaq Global Select Market.

The completion arrives after Viatris had already lifted its 2026 guidance and disclosed a US$1.65 billion Pacira acquisition as part of its recent results update. The final filing puts the aggregate amount payable in the offer and merger at approximately US$1.69 billion, with the difference from the earlier reported figure not explained in this announcement.

Revenue contribution starts before year-end

Viatris expects Pacira to add total revenue of between US$90 million and US$100 million from November 17 through December 31, 2026. That is management’s near-term revenue expectation, not a reported contribution, and the filing does not quantify the acquisition’s expected earnings impact, synergies, integration costs or financing costs.

The next material test will therefore come through Viatris’ financial reporting: whether Pacira delivers the expected revenue contribution, how the business affects earnings and cash generation, and what costs accompany the integration of the newly acquired operation.

Get NASDAQ:VTRS news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The transaction is complete, but its investment case now shifts from deal certainty to evidence of revenue, earnings and integration benefits.

Questions in the middle?

  • Will Pacira’s December revenue contribution land within Viatris’ US$90 million to US$100 million expectation?
  • How will short-term borrowings and integration costs affect the acquisition’s earnings and cash-flow contribution?
  • When will Viatris quantify any synergies or longer-term earnings benefits from Pacira’s non-opioid pain portfolio?

Sources

1